Table 3 – Cost effectiveness of different treatment paradigms for BP lowering relative to current practice
Treatment paradigm for BP lowering | Population treated n (%) | CVD events averted over 10 years due to treatment | Treatment costs for patients at high risk of CVD (USD millions) | Hospitalization costs for CVD events (USD millions) | Incremental cost relative to current practice (USD millions) | Incremental CVD events averted relative to current practice | Incremental cost per CVD event averted relative to current practice (USD) | Incremental cost per DALY averted relative to currentpractice (1 CVD event = 22.5 DALYs)a |
|---|---|---|---|---|---|---|---|---|
Current practice | 12,190 (19.6) | 502 | 4.4 | 0.10 | ||||
Treatment of “hypertension” (BP > 140/90 mmHg) | 13,061 (32.6) | 869 | 7.3 | 0.18 | 2.8 | 367 | 7723.0 | 342.9 |
Treatment according to NPCDCS guidelines | 13,061 (21.0) | 886 | 4.7 | 0.18 | 0.2 | 384 | 608.3 | 27.0 |
Treatment of all at intermediate and high risk | 14,429 (23.2) | 936 | 5.2 | 0.19 | 0.7 | 434 | 1649.2 | 73.2 |
Treatment of all at high risk | 11,133 (17.9) | 812 | 4.0 | 0.17 | −0.4 | 310 | Cost saving | Cost saving |
Treatment of all above 45 years of age | 47,578 (76.5) | 1233 | 17.1 | 0.26 | 12.6 | 731 | 17,219.9 | 764.7 |
Treatment of all above 55 years of age | 27,676 (44.5) | 909 | 9.9 | 0.19 | 5.5 | 407 | 13,434.9 | 596.6 |